Clinical trials: Prostate Cancer Detection
Prostate Cancer
FACBC PET/CT for Recurrent Prostate Cancer
Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients.
- Trial name
- NCT00562315
- Testing
- FACBC, ProstaScinct
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- David M. Schuster, MD
Prostate Cancer, Clinically Significant Prostate Cancer
Transperineal Versus Transrectal Cognitive Fusion Prostate Biopsy
This prospective randomized controlled trial aims to compare transperineal and transrectal cognitive fusion prostate biopsy techniques in patients with suspicious prostate lesions detected by multiparametric magnetic resonance…
- Conditions
- Prostate Cancer, Clinically Significant Prostate Cancer, Cognitive Fusion
- Trial name
- PROCOG (NCT07710807)
- Testing
- Transrectal Cognitive Fusion Prostate Biopsy, Transperineal Cognitive Fusion Prostate Biopsy
- Where
- Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Ankara Etlik City Hospital
Prostate Cancer
For Cause Prostate Biopsy in REDUCE Population Trial
The REDUCE trial was conducted to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease.
- Trial name
- NCT01529086
- Where
- United States
- Volunteers
- 6,608 people
- Sponsor
- The Cleveland Clinic
Previous Negative Biopsy
Ultrasound Based Transperineal Robotic Biopsy of the the Prostate
The objective of the study is to examine the effectiveness and accuracy of the BioXbot in prostate biopsy as opposed to transrectal biopsy.
- Trial name
- BxB (NCT01102361)
- Testing
- Robotic Transperineal Biopsy
- Where
- Singapore
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Prostate Cancer, Prostate Neoplasm
MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection
With the general acceptance of MRI and technical advances in biopsy technique of the prostate, new questions arise concerning the selection of patients, the approach, the appropriate technique, the lesions to target and the…
- Trial name
- PROSOVI (NCT03819751)
- Testing
- MRI-targeted prostate biopsy
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer
Choline PET/CT vs. MeAIB PET/CT in Prostate Cancer
Prostate cancer is currently the leading newly diagnosed cancer in the industrialized world. Treatment of prostate cancer is highly dependent on the stage of the disease.
- Trial name
- NCT02232672
- Testing
- Choline PET/CT and MeAIB PET/CT
- Where
- Denmark
- Sponsor
- Odense University Hospital
Prostate Cancer
Accuracy of mpMRI and MRI-targeted, Ultrasound-navigated Prostate Fusion Biopsy in Detection of Prostate Cancer
The investigators examined whether a high PI-RADS v2 score correlates with the presence of prostate cancer. In addition, the investigator inspected whether the lesion size as determined by mpMRI correlates with the presence of…
- Trial name
- NCT03615131
- Testing
- MRI-TRUS fusion prostate biopsy
- Where
- Switzerland
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Kantonsspital Winterthur KSW
Prostate Cancer
Multiparametric Ultrasound-Study for the Detection of Prostate Cancer
The primary objective of the study is the matching of sensitivity, specificity, the negative predicate value and the positive predictive value of Contrast-Enhanced Ultrasound (CEUS), Shear Wave Elastography (SWE) and the…
- Trial name
- NCT03091231
- Testing
- mpUS multiparametric Ultrasound
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Martini-Klinik am UKE GmbH
Prostate Cancer
Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion High Dose Rate (HDR) Prostate Brachytherapy
The Magnetic Resonance (MR) provides high resolution of soft tissue images allowing an appropriate assessment of the local extent of the disease.
- Trial name
- BRAPROST (NCT01909388)
- Testing
- MRI-TRUS fusion guided real time HDR
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Alfonso Gomez-Iturriaga
Prostate Cancer
Prostate Cancer Awareness and Initiative for Screening in the European Union
PRAISE-U was initiated on the 1st of April 2023 and is set to last for three years. This collaborative effort involves 25 institutions across 12 countries, all driven by a shared objective: to rationalize prostate cancer…
- Trial name
- PRAISE-U (NCT06424275)
- Testing
- Risk-based screening algorithm
- Where
- 5 sites in Ireland, Lithuania and 2 more
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- European Association of Urology Research Foundation
Prostate Cancer
Application of a Novel Model Based on Plasma cfDNA Assay and MRl Imaging in the Detection of Prostate Cancer
The goal of this diagnostic test is to obtain multiple cell-free DNA （cfDNA） fragment profiles of subjects by whole genome sequencing based on plasma cfDNA, build a prostate cancer prediction model by machine learning, and to…
- Trial name
- NCT06509919
- Testing
- Blood draw and MRI scans
- Where
- 10 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Shanghai Changzheng Hospital
Prostate Neoplasm
PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?
This evaluates the detection rates of prostate cancer by MRI-targeted prostate biopsy compared to standard 12-core trans-rectal ultrasound guided (TRUS) prostate biopsy.
- Trial name
- PRECISION (NCT02380027)
- Testing
- MRI, MRI-targeted biopsy, TRUS-biopsy
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- University College, London
Prostate Carcinoma
MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial
This clinical trial studies how well a magnetic resonance imaging (MRI)-based machine learning approach (i.e., artificial intelligence [AI]) works as compared to radiologist MRI readings in detecting prostate cancer.
- Trial name
- NCT07162194
- Testing
- Targeted Prostate Biopsy, Prostate Imaging Reporting & Data System, Deep Learning Artificial Intelligence
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Southern California
PROSTATE CANCER, Prostate Biopsy
Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection
The goal of this cohort study is to investigate multiparametric ultrasound versus multiparametric MRI for clinically significant prostate cancer detection in patients scheduled for initial biopsy.
- Trial name
- TRUSVSMPMRI (NCT06183905)
- Testing
- Prostate imaging, Prostate biopsy
- Where
- China
- Volunteers
- 635 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
High-risk Prostate Cancer
Contribution of Canine Detection in the Diagnostic Strategy of High-risk Prostate Cancer (Prostate-K9-Detect)
The sense of smell allows both humans and dogs to carry out a chemo-sensory analysis of their environment. Volatile organic compounds enter the nasal cavities and bind to receptors in the nasal mucosa.
- Trial name
- NCT05558735
- Testing
- urine collection, canine detection
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostatic Neoplasms, Neoplasm Metastasis
Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients
For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment. Standard treatment for these patients is radiotherapy or surgery.
- Trial name
- NCT04790968
- Testing
- PSMA-PET, PSMA-PET/MRI, PSMA-PET/CT
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Norwegian University of Science and Technology
Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason Classification, Establish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the Technique
Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis
Objectives: To establish if there are differences between an ultrasound-guided transrectal prostate biopsy (BPTE) and a transperineal prostatic biopsy (BPTP) with and without a multiparametric Magnetic Resonance (RMmp) in…
- Conditions
- Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason Classification, Establish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the Technique, Establish the Efficacy Between the Four Schemes in Terms of the Patient's Subjective Perception Regarding Pain and Quality of Life, Establish the Association of the Tumor Biomarker in the Early Detection and Aggressiveness of Tumors
- Trial name
- RMPBX201801 (NCT04283032)
- Testing
- Multiparametric magnetic resonance
- Where
- Spain
- Volunteers
- 628 people
- Sponsor
- InvestigatorUrologyIBSAL
Prostate Carcinoma
An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer
This trial studies the use of magnetic resonance imaging (MRI) with Dixon based imaging sequences in detecting prostate cancer. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas…
- Trial name
- NCT05047965
- Testing
- Dixon MRI, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Prostate Cancer
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
This phase II trial studies how well fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) and whole body and axial magnetic resonance imaging (MRI) work in finding metastases in patients with…
- Trial name
- NCT01967862
- Testing
- computed tomography, bone scan, 3-Tesla magnetic resonance imaging
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Thoracic Cancer, Ovarian Cancer
Project CADENCE (CAncer Detected Early caN be CurEd)
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be…
- Conditions
- Thoracic Cancer, Ovarian Cancer, Liver Cancer, Prostate Cancer
- Trial name
- CADENCE (NCT05633342)
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiRXES Pte Ltd